Cargando…
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483343/ https://www.ncbi.nlm.nih.gov/pubmed/36779591 http://dx.doi.org/10.3324/haematol.2022.281636 |
| _version_ | 1785102354579718144 |
|---|---|
| author | Ruhnke, Leo Röllig, Christoph Herold, Sylvia Sauer, Tim Brandts, Christian H. Steffen, Björn Schäfer-Eckart, Kerstin Krause, Stefan W. Hänel, Mathias Reichle, Albrecht Scholl, Sebastian Neubauer, Andreas Mikesch, Jan-Henrik Schetelig, Johannes Stölzel, Friedrich Kramer, Michael Haake, Annett Frimmel, Julia Krämer, Alwin Schlenk, Richard Platzbecker, Uwe Serve, Hubert Baldus, Claudia D. Müller-Tidow, Carsten Aust, Daniela Bornhäuser, Martin Ehninger, Gerhard Thiede, Christian |
| author_facet | Ruhnke, Leo Röllig, Christoph Herold, Sylvia Sauer, Tim Brandts, Christian H. Steffen, Björn Schäfer-Eckart, Kerstin Krause, Stefan W. Hänel, Mathias Reichle, Albrecht Scholl, Sebastian Neubauer, Andreas Mikesch, Jan-Henrik Schetelig, Johannes Stölzel, Friedrich Kramer, Michael Haake, Annett Frimmel, Julia Krämer, Alwin Schlenk, Richard Platzbecker, Uwe Serve, Hubert Baldus, Claudia D. Müller-Tidow, Carsten Aust, Daniela Bornhäuser, Martin Ehninger, Gerhard Thiede, Christian |
| author_sort | Ruhnke, Leo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10483343 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104833432023-09-08 Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial Ruhnke, Leo Röllig, Christoph Herold, Sylvia Sauer, Tim Brandts, Christian H. Steffen, Björn Schäfer-Eckart, Kerstin Krause, Stefan W. Hänel, Mathias Reichle, Albrecht Scholl, Sebastian Neubauer, Andreas Mikesch, Jan-Henrik Schetelig, Johannes Stölzel, Friedrich Kramer, Michael Haake, Annett Frimmel, Julia Krämer, Alwin Schlenk, Richard Platzbecker, Uwe Serve, Hubert Baldus, Claudia D. Müller-Tidow, Carsten Aust, Daniela Bornhäuser, Martin Ehninger, Gerhard Thiede, Christian Haematologica Letter to the Editor Fondazione Ferrata Storti 2023-02-09 /pmc/articles/PMC10483343/ /pubmed/36779591 http://dx.doi.org/10.3324/haematol.2022.281636 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Ruhnke, Leo Röllig, Christoph Herold, Sylvia Sauer, Tim Brandts, Christian H. Steffen, Björn Schäfer-Eckart, Kerstin Krause, Stefan W. Hänel, Mathias Reichle, Albrecht Scholl, Sebastian Neubauer, Andreas Mikesch, Jan-Henrik Schetelig, Johannes Stölzel, Friedrich Kramer, Michael Haake, Annett Frimmel, Julia Krämer, Alwin Schlenk, Richard Platzbecker, Uwe Serve, Hubert Baldus, Claudia D. Müller-Tidow, Carsten Aust, Daniela Bornhäuser, Martin Ehninger, Gerhard Thiede, Christian Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial |
| title | Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial |
| title_full | Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial |
| title_fullStr | Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial |
| title_full_unstemmed | Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial |
| title_short | Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial |
| title_sort | midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and kit and/or flt3-itd mutations: results of the sal midokit trial |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483343/ https://www.ncbi.nlm.nih.gov/pubmed/36779591 http://dx.doi.org/10.3324/haematol.2022.281636 |
| work_keys_str_mv | AT ruhnkeleo midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT rolligchristoph midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT heroldsylvia midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT sauertim midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT brandtschristianh midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT steffenbjorn midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT schafereckartkerstin midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT krausestefanw midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT hanelmathias midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT reichlealbrecht midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT schollsebastian midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT neubauerandreas midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT mikeschjanhenrik midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT scheteligjohannes midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT stolzelfriedrich midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT kramermichael midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT haakeannett midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT frimmeljulia midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT krameralwin midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT schlenkrichard midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT platzbeckeruwe midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT servehubert midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT baldusclaudiad midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT mullertidowcarsten midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT austdaniela midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT bornhausermartin midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT ehningergerhard midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial AT thiedechristian midostaurininadditiontointensivechemotherapyinacutemyeloidleukemiawitht821andkitandorflt3itdmutationsresultsofthesalmidokittrial |